Reviews/Anti Amyloid Antibodies/Lecanemab slows decline in early Alzheimer's disease
Efficacy · AMAB-EFF-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
A large, well-controlled 18-month trial tested whether lecanemab slows the worsening of thinking and daily function in people with early Alzheimer's disease, and found that people on the drug declined less than those on placebo on the main clinical measure [5]. The same direction of benefit showed up again when the trial data were broken out by gene status [1], extended to three years [6], and examined in Asian participants [7], and it appeared in several real-world clinics treating patients outside the trial [12][17]. One real-world group in China, however, saw no measurable improvement in thinking over a short follow-up [3]. The panel concluded the drug does slow clinical decline because the controlled trial result is clear and repeatedly echoed, while noting the benefit is modest in size and that nearly all the rigorous evidence comes from one trial. The real-world and modelling studies support the picture but do not independently prove it.
The pivotal double-blind placebo-controlled trial [5] reports a statistically significant slowing on the clinical primary endpoint CDR-SB (difference -0.45; 95% CI -0.67 to -0.23; P<0.001), with secondary cognitive and functional endpoints also favouring lecanemab (ADAS-cog14 -1.44; ADCOMS -0.050; ADCS-MCI-ADL 2.0). The direction is reproduced in the ApoE subgroup [1], sustained through the 36-month open-label extension [6], and consistent in the Asian regional cohort [7]. Real-world multicentre cohorts report significantly attenuated decline versus a matched natural-history comparator [12] and stable short-term cognition [17]. Modelling work [2][14] projects the slowing into longer time horizons but does not measure it directly. The contested point: The evidence divides on whether a modest, largely single-trial effect carries clinical weight: the CDR-SB difference of -0.45 on an 18-point scale [5] is small, and a real-world cohort [3] reports no measurable cognitive efficacy at short-term follow-up. The panel treated the direction as robust while conceding the magnitude and the near-total reliance on the Clarity AD trial family [1][6][7] as genuine limitations.
All 21 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Anti Amyloid Antibodies, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The absolute effect is small: a CDR-SB difference of -0.45 on an 18-point scale [5]; 'slows' is defensible directionally but clinical meaningfulness of the magnitude is not established by this corpus.
Evidential independence is weak: [1], [6] and [7] are all subgroups/extensions of the single Clarity AD trial [5], so the blinded evidence is effectively one trial, not independent replication.
Where it remains uncertain. The absolute effect is small on an 18-point scale and almost all blinded evidence comes from one trial family [1][6][7]; one real-world cohort reported no measurable cognitive efficacy [3].
Aleatory
The Asian regional subgroup estimate has a confidence interval crossing zero (-0.773 to 0.076) [7], reflecting imprecision from the smaller sample.
Epistemic
The corpus does not establish whether a -0.45 CDR-SB difference on an 18-point scale [5] is clinically meaningful.
Inferential
Projections of years of progression delayed [2] and continued separation over 4 years [14] are simulations assuming the trial effect, not measured decline.
The load-bearing papers from a corpus of 21, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Replicates the primary effect in the largest subgroup (85% of the trial).
“Lecanemab significantly reduced clinical decline on CDR-SB at 18 months compared to placebo in the ApoEε4 heterozygotes or non-carriers subgroup.”
Panel auditInternal validity: high · scope of inference: Early-AD ApoE ε4 heterozygotes/non-carriers (85% of Clarity AD), CDR-SB over 18 months with OLE to 36 months.Key limitations: subgroup analysis · no numeric effect size in abstract · OLE comparison is open-label vs natural-history cohort
Primary blinded RCT evidence of statistically significant slowing on the clinical CDR-SB endpoint.
“Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events.”
Panel auditInternal validity: high · scope of inference: Persons 50-90 with MCI or mild dementia due to AD and confirmed amyloid, over 18 months.Key limitations: 18-month duration · absolute CDR-SB difference small · adverse events including ARIA and infusion reactions
Extends durability of the slowing to 36 months (open-label).
“Results presented in our paper demonstrate that lecanemab continued suppression of amyloid plaque levels and significantly slowed clinical decline on multiple measures of cognition, function, and quality of life in early AD at 18 months and continued for 36 months to date.”
Panel auditInternal validity: medium · scope of inference: Long-term (to 36 months) clinical, HRQoL and safety outcomes in early-AD participants continuing or starting open-label lecanemab.Key limitations: open-label extension · no concurrent placebo beyond 18 months · no numeric effect sizes in abstract
A 37% treatment-related time delay was applied as an assumption derived from Clarity AD, so the paper presupposes the effect and cannot itself evidence it.
Panel auditInternal validity: not assessable from abstract · scope of inference: Projected years of progression delay from MCI to severe AD assuming a fixed Clarity AD-derived treatment effect.Key limitations: simulation/modeling · effect assumed not tested · results contingent on model assumptions
4 of 21 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A blinded phase 3 RCT with a significant clinical primary endpoint plus concordant replications establishes the directional claim, tempered only by modest effect size and limited independence.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent confirmatory RCT. Nearly all blinded evidence is Clarity AD [5][1][6][7]; the direction rests on one trial family. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A second double-blind placebo-controlled phase 3 trial run by an independent sponsor in early AD.
Open question: Does an independent sponsor's placebo-controlled trial reproduce the CDR-SB slowing seen in Clarity AD? Why it is still open: All blinded evidence in the corpus is the single Clarity AD trial family [5][1][6][7].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19